What are you trying to understand?
Peptides, hormones, cholesterol, memory, and training. Clear answers grounded in research, with the evidence and its limits explained.
Choose a topic
116 common questions · 6 research guides
Sorted by editorial relevanceHow these questions are selected
We combine reader-requested topics and foundational questions with recurring themes in Vigorous Steve’s and Big Paul’s public Q&A listings and chapter indexes. The Q&A selections draw on 100 screened episode listings from each creator and selected chapter lists. It is an editorial selection, not a complete transcript analysis or a measured frequency ranking.
Answers are independently written from research and clinical sources. Creator links identify where a question arose; they are not endorsements or evidence for the answer. Default ordering balances broad usefulness, recurring themes, and foundational context. Search prioritizes matching titles, then descriptions and answer text. Topic counts overlap because a question can belong to several topics.
Vigorous Steve Q&A archive · Anabolic Bodybuilding Q&A archive
Can myostatin inhibitors preserve muscle during GLP-1 weight loss?
What trevogrumab and taldefgrobep can—and cannot—tell us about muscle preservation.
Early human body-composition evidence; functional benefits remain uncertainCould one gene-editing treatment replace years of cholesterol medication?
What VERVE-102 has shown, and why durable editing requires long follow-up.
Small open-label phase 1 study; cardiovascular-event benefit not establishedCan targeting inflammation slow aging or reduce cardiovascular risk?
BGE-102 separates a promising biomarker effect from an unproven longevity claim.
Phase 1 sponsor-reported biomarkers; phase 2 clinical research ongoingCan protecting brain-cell connections help treat dementia?
Zervimesine’s exploratory findings and the limits of the SHIMMER trial.
Randomized phase 2 safety and exploratory findings; confirmatory efficacy neededHas cellular age reversal actually been demonstrated in humans?
What the ER-100 eye trial can test without implying whole-body rejuvenation.
Animal rationale; first-in-human phase 1 safety studyWhat makes amycretin, now called zenagamtide, different from tirzepatide?
Receptor targets, oral versus injectable formulations, and why headline percentages do not rank drugs.
Published phase 2 studies; cross-trial superiority not establishedWhat is brenipatide, and how is it different from tirzepatide and retatrutide?
Shared incretin targets do not make these investigational and established medicines interchangeable.
Receptor targets are documented; these sources do not show superiority over other drugsCould brenipatide reduce alcohol cravings, and what are the trials actually measuring?
Drinking outcomes, craving and durable recovery are related but distinct measures.
Phase 3 trials are testing efficacy; another incretin drug’s results are contextual evidenceWhy is a GIP/GLP-1 drug like brenipatide being studied for depression and bipolar disorder?
Relapse-prevention studies test a clinical hypothesis without establishing an antidepressant or mood-stabilizing effect.
Adjunctive mood-disorder trials are underway; efficacy cannot be inferred from mechanismCould brenipatide help prevent a return to smoking?
The smoking trial focuses on maintaining abstinence after quitting, which differs from helping someone quit initially.
Placebo-controlled relapse-prevention trial; benefit has not been established by the trial listingWhat do we actually know about brenipatide’s benefits and safety so far?
Separate confirmed identity, trial plans, conference disclosures and completed clinical outcome evidence.
Investigational development with public trial designs and conference disclosures; major outcome questions remainCan psilocybin help treatment-resistant depression, and how long do the benefits last?
Evidence for rapid improvement is stronger than the claim that one session permanently resolves depression.
Randomized trials support short-term benefit in selected patients; durability variesDoes psilocybin work better than antidepressants like escitalopram?
A direct comparison is informative, but a small trial did not establish superiority or equivalence.
Small head-to-head trial found no significant difference on its primary outcomeCan psilocybin help people stop drinking or reduce heavy alcohol use?
A randomized trial supports reduced heavy drinking within a structured psychotherapy program.
Promising randomized evidence for alcohol use disorder; not proof of a universal addiction cureCan psilocybin reduce anxiety, depression and fear of death in people with cancer?
Landmark trials address psychological distress and quality of life, not treatment of the cancer itself.
Small randomized trials show substantial distress reduction; long-term comparisons have limitationsIs psilocybin safe, and why do clinical trials screen people so carefully?
Selected, monitored participants cannot establish safety for everyone or for unsupervised use.
Clinical safety data are conditional on screening and support; important psychiatric and physical risks remainDoes methylene blue actually improve energy and brain function in healthy people, or are the benefits mostly theoretical?
A small human memory experiment is a starting point, not proof of lasting energy or cognitive enhancement.
Small acute human study; sustained benefits in healthy people remain unestablishedWhy can methylene blue interact dangerously with antidepressants, and who else should avoid it?
Serotonin toxicity, G6PD deficiency and why an oral product is not an automatic safety exemption.
Serious drug interactions and hemolysis are established safety concernsDoes methylene blue have meaningful evidence for Alzheimer’s disease, and how do experimental derivatives differ from ordinary methylene blue?
Tau-targeting formulations, primary trial endpoints and why online drops are not interchangeable with a studied medicine.
Investigational formulation data are mixed and do not establish ordinary methylene blue as an Alzheimer’s treatmentDoes NAC improve lung health, mental health or recovery, and which benefits have convincing human evidence?
Benefits depend on the condition; antioxidant biology does not establish a general recovery supplement.
Condition-specific respiratory evidence; psychiatric and general recovery claims are less certainIs taking glutathione better than taking NAC, and do oral, liposomal and intravenous forms produce different results?
Absorption and blood antioxidant levels do not establish which product improves health or energy.
Biomarker studies exist; superiority for meaningful wellness outcomes is not establishedDoes turmeric or curcumin meaningfully reduce inflammation and joint pain, and does the formulation matter?
Some pain relief is plausible, but that is different from repairing cartilage or treating every inflammatory condition.
Short-term osteoarthritis trials suggest symptom benefit; broader and structural claims remain uncertainDoes vitamin D improve immunity, mood or testosterone when you’re already getting enough?
Correcting a shortfall and adding more on top of adequate intake are different interventions.
Trials do not support a reliable broad boost in vitamin-D-replete adultsDoes vitamin K2 actually prevent calcium from building up in arteries, or is that claim ahead of the evidence?
A new trial supports slower calcification progression in a specific population, without proving plaque reversal or fewer heart attacks.
2026 trial supports slower CAC progression with K2 plus D3; clinical event benefit remains unprovenDo fish oil supplements protect the heart and brain, and why do some studies suggest an increased risk of atrial fibrillation?
Prescription EPA, mixed omega-3 products and brain-health supplements do not have interchangeable evidence.
Cardiovascular results depend on product and population; high-dose trials raise atrial fibrillation concernsWhat does ivermectin actually treat, and how strong is the evidence for uses beyond parasitic infections?
An effective medicine for specific indications is not automatically an effective antiviral or anticancer treatment.
Established specific antiparasitic uses; randomized COVID-19 trials have not shown meaningful benefitDoes low-dose naltrexone help chronic pain, fatigue or autoimmune symptoms, and how is it different from standard-dose naltrexone?
Off-label low-dose use has an interesting rationale, but larger pain trials have tempered early enthusiasm.
Mixed and limited evidence; larger fibromyalgia trials have not established a consistent pain benefitDoes psilocybin microdosing improve mood, creativity or focus beyond placebo?
Testimonials and noticeable drug effects are different from a reproducible improvement in function.
Small blinded studies have not established reliable mood, creativity or cognitive benefitsHow do ketamine and esketamine help depression, and how durable are the benefits?
Rapid improvement is possible, but lasting benefit often requires continued treatment and monitoring.
Clinical efficacy and maintenance evidence exist; response and durability varyCan ibogaine help addiction, PTSD or traumatic brain injury, and what makes its cardiac risks important?
Promising observational findings need controlled confirmation, and cardiac toxicity is a central limitation.
Early human signals; efficacy remains uncertain and serious cardiac toxicity is documentedDoes hyperbaric oxygen therapy improve cognition, recovery or healthy aging, and which uses actually have good evidence?
Established medical indications and emerging cognitive studies should not be bundled into a universal anti-aging claim.
Established condition-specific medical uses; broad wellness and longevity claims remain unprovenDo peptides actually work, or is this all placebo?
Real medicines, experimental molecules, and the evidence separating them.
Strong human evidence for some drugs; major gaps for othersHow do PCSK9 inhibitors like Repatha lower cholesterol, and how are they different from statins?
Different liver pathways, a shared LDL goal, and the distinction between lowering a number and preventing events.
Randomized trials demonstrate LDL lowering and cardiovascular benefit for PCSK9 antibodiesIs ApoB more useful than LDL cholesterol for understanding heart disease risk?
Cholesterol cargo and the number of atherogenic particles can tell different stories.
Cohort data support ApoB for resolving discordant lipid resultsWhat’s the difference between normal forgetfulness, mild cognitive impairment, and Alzheimer’s disease?
The pattern, persistence and effect on daily independence matter more than an isolated lapse.
Clinical assessment distinguishes cognitive syndromes and investigates their causesWhat is eloralintide, and how is it different from cagrilintide or a GLP-1 drug?
An emerging amylin approach with human trial evidence.
Phase 2 evidence for eloralintide; cross-trial superiority is not establishedDoes more testosterone always produce more muscle?
Dose-response evidence, diminishing practical returns, and individual variation.
Controlled human evidence for a dose response; no universal optimal doseDo you need heavy weights to build muscle, or can lighter weights work?
Effort and progression matter, but strength goals still affect the choice.
Controlled evidence supports hypertrophy across a range of loadsIs more training volume always better for muscle growth?
More useful work can help; more sets alone do not guarantee more progress.
Higher volume helped some outcomes in a short trial; no unlimited dose response is establishedAre peptides safe long-term, or do we just not know yet?
What years of follow-up can establish, and what short studies cannot.
Long-term evidence varies substantially by molecule and populationHow do GLP-1 agonists actually cause fat loss beyond appetite suppression?
Brain signals, glucose regulation, and what “metabolic effects” really means.
Human mechanistic trials support reduced energy intakeIs retatrutide just a stronger version of tirzepatide?
Three receptor targets do not automatically mean a better option for everyone.
Distinct mechanisms and substantial trial effects; individual superiority is not automaticDoes fasted cardio burn more body fat over time?
Fuel used during a workout is not the same as fat lost over several weeks.
Small controlled trials have not established a clear body-fat advantageDoes fasted weight training reduce muscle growth if daily calories and protein are the same?
Long-term training results matter more than a single fasted-versus-fed snapshot.
A small randomized trial found similar adaptations; precise equivalence remains uncertainDoes creatine cause water retention, hair loss, or kidney damage, and which concerns have human evidence?
Three different claims, with very different levels of support.
Water-related weight gain is expected; controlled trials do not support the common hair and kidney claims in healthy adultsIf bloodwork looks good, is staying on a cycle or TRT-plus year-round safe?
Normal routine labs do not measure cumulative exposure or every organ outcome.
Normal blood tests cannot rule out cardiovascular injuryCan testosterone or anabolic steroids enlarge the heart even when blood pressure and bloodwork look normal?
Why a normal laboratory panel cannot assess heart structure or pumping function.
Prospective imaging and observational cohorts link AAS exposure to cardiac changesDoes elevated estradiol always need an aromatase inhibitor?
Estradiol has useful functions; a lab flag is only part of the picture.
Human evidence supports a role for estrogen in male body composition and sexual functionIs puffy chest tissue gynecomastia, body fat, or both?
Why the diagnosis matters before reaching for an estrogen blocker.
Clinical evaluation distinguishes glandular tissue from fatWhy does testosterone cause acne, and does it mean estrogen is too high?
An oil-gland response is not a diagnostic test for estradiol.
Androgen-related acne is recognized; severity does not diagnose estrogen excessDo growth hormone peptides actually raise GH, or is that just marketing?
A measurable hormone response is real, but it is not the same as proven muscle growth.
Small human studies demonstrate hormone responsesIs MK-677 basically oral HGH, and why does it make people hungry?
A ghrelin-receptor drug is not swallowed growth hormone.
Human trials show hormonal effects and appetite changes, with glucose tradeoffsDoes hCG preserve fertility on TRT, and is it useful if you plan to stay on testosterone?
Maintaining testicular signaling is not the same as proving fertility.
Human mechanistic evidence supports testicular stimulation; sperm outcomes need measurementWhat’s the actual difference between BPC-157 and TB-500 for healing?
Different repair hypotheses, with no established need to combine them.
Mostly preclinical; human combination benefits are unprovenDoes GHK-Cu actually improve skin and collagen, and how does topical evidence compare with injections?
A plausible repair mechanism does not establish that systemic injections outperform a cream.
Small topical human studies and laboratory findings exist; systemic cosmetic injection benefits remain unestablishedDoes KPV have meaningful human evidence for inflammation or gut health, or are the claims mostly based on animal studies?
Human cell lines, mouse colitis and clinical treatment are three different evidence levels.
Mechanistic and mouse studies provide rationale; convincing clinical efficacy is not establishedHow can you preserve muscle during a cut when GLP-1s make eating difficult?
Adequate protein and productive training remain central.
Human nutrition trials support protein and exercise; direct GLP-1 athlete data are limitedCan poor sleep limit muscle growth even if diet and training are good?
Recovery has measurable biology beyond how motivated you feel.
Short human experiments show reduced muscle protein synthesis with sleep restrictionCan sleep apnea explain high hematocrit, fatigue, or poor results on TRT?
Interrupted breathing can be an overlooked contributor when changing testosterone does not solve the problem.
Observational TRT data link sleep apnea with polycythemia; symptoms require diagnostic assessmentDoes taking melatonin every night reduce your natural production, and is more actually better?
Circadian timing, formulation and long-term uncertainty matter more than a bigger dose.
Specific adult studies found no suppression after withdrawal; this does not establish every dose as safe indefinitelyDo more frequent testosterone injections improve results, and when should bloodwork be taken?
Peaks, troughs, and why comparable blood draws matter.
Formulation and sampling time matter; daily injection is not universally superiorWhy can total testosterone look normal while free testosterone is low, and what role does SHBG play?
Understanding hormone binding before interpreting a seemingly contradictory blood test.
Guidelines recommend reliable free-testosterone assessment when SHBG alters interpretationWhat should a rising hematocrit mean, and is regular blood donation the answer?
Address the driver, and keep iron status in view.
Androgens can raise hematocrit; donation is not a universal long-term fixWhat’s the deal with peptide purity and testing? How do I know what I’m actually getting?
What a certificate of analysis can establish, and what it leaves unanswered.
Identity, amount, impurities, and microbiological quality require distinct checksCan an IGF-1 result prove that HGH is genuine and correctly dosed?
A blood response measures your biology, not the full contents of a vial.
IGF-1 helps assess GH activity; it is not a product-quality certificateDoes HGH build actual muscle, or mostly increase water and lean mass measurements?
Separate lean mass, muscle tissue, strength, and sprint performance.
Controlled trials show body-composition effects with limited strength benefitsWhy can HGH make your hands numb or your rings feel tight?
Fluid retention and nerve compression are not signs of better muscle growth.
Somatropin labels recognize dose-related edema and nerve-compression symptomsIs HGH better in the morning, before bed, or around a workout?
A natural nighttime pulse does not establish an optimal bodybuilding schedule.
Timing studies do not establish a superior hypertrophy schedule in healthy adultsWhy does blood pressure rise on a cycle, and is adding a blood-pressure drug enough?
Blood pressure, fluid changes, and heart structure need separate attention.
Prospective studies show blood-pressure and cardiac changes during AAS useCan you become desensitized to GLP-1 agonists, and do they stop working permanently?
A plateau does not show that your receptors are permanently damaged.
Sustained multi-year benefit is demonstrated; permanent receptor shutdown is notWhy do anabolic steroids worsen cholesterol, and can supplements cancel that out?
Lipid changes are a risk signal, not just an inconvenient lab flag.
Prospective human evidence shows adverse lipid changes during AAS useWho actually benefits from a PCSK9 inhibitor, and when should one be considered?
Why inherited cholesterol, existing artery disease and absolute risk matter more than chasing the lowest number.
Benefit is demonstrated in selected higher-risk populations, not universal preventive useWhat’s the difference between Repatha, Praluent, and inclisiran, and are their heart-protection benefits equally established?
Antibodies bind PCSK9; inclisiran reduces its production. Similar LDL effects do not mean identical outcome evidence.
Antibody outcome trials are established; inclisiran outcome evidence must be assessed separatelyWhat is lipoprotein(a), and what can you do if it’s high despite otherwise good cholesterol?
An inherited risk factor that can remain elevated despite a healthy lifestyle or a reassuring LDL result.
Lp(a) predicts risk; lowering it and proving clinical benefit are separate questionsCan lowering cholesterol actually reverse artery plaque, or does it mainly prevent further buildup?
What coronary imaging trials mean by regression, and why it is not a clean-out of the arteries.
Imaging trials show modest average regression; outcome trials demonstrate fewer cardiovascular eventsCan cholesterol get too low, and could that affect testosterone, hormones, or brain function?
Why blood LDL is not the same thing as the cholesterol supply inside every cell.
Evolocumab trials are reassuring for cognition and steroid hormones within studied populations and follow-upDo statins interfere with muscle growth or exercise performance, and how do ezetimibe and bempedoic acid compare?
Distinguishing muscle symptoms, performance testing and actual hypertrophy outcomes.
Muscle symptoms occur in a minority; performance trials do not establish a universal block on hypertrophyIf Cardarine improves cholesterol, does that mean it is heart-safe?
A favorable biomarker cannot establish overall safety.
Short human lipid trials do not resolve serious preclinical toxicity concernsHow long does natural testosterone and fertility take to recover after stopping steroids?
Hormone recovery and sperm recovery run on different timelines.
Prospective human data show variable recovery, often slower for sperm productionCan peptides cause cancer or accelerate existing cancer?
Why stimulating growth is a concern, without assuming every peptide causes cancer.
Risk depends on the pathway; experimental products have major long-term gapsWhat’s the difference between research peptides and pharmaceutical peptides?
The molecule may sound the same; the evidence and quality controls may not be.
Product identity, quality, and approval must be checked separatelyWhy can libido or erections get worse even when testosterone is high?
Hormone exposure is only one part of sexual function.
Sexual function depends on more than total testosteroneDoes nandrolone raise prolactin, and does a high prolactin result explain sexual side effects?
Separating a popular explanation from a confirmed hormonal diagnosis.
High prolactin can impair sexual function; a universal nandrolone-to-prolactin explanation is not establishedDoes nandrolone heal joints, or just make them feel better?
Pain relief and structural repair are different claims.
A small human pilot suggests pain relief; joint regeneration is unprovenCan HGH cause insulin resistance, and does adding insulin fix the problem?
A lower glucose reading does not prove normal insulin sensitivity.
GH-axis therapies can worsen glucose tolerance; insulin adds hypoglycemia riskCan metformin reduce muscle gains from training?
A real trial signal, with important limits on who it applies to.
A randomized trial found reduced hypertrophy in older adultsDoes high creatinine mean kidney damage in a muscular person?
Muscle affects the measurement, but kidney injury still needs to be excluded.
Creatinine needs context; proteinuria is not explained away by muscularityDoes cardio interfere with muscle growth, and how should you judge the tradeoff?
The dose and recovery cost matter more than labeling all cardio catabolic.
Controlled studies show that concurrent training can improve fitness without blocking hypertrophyCan SLU-PP-332 replace cardio, or is the “exercise pill” label misleading?
Exercise-like gene activity is a starting point, not a complete workout.
Published efficacy evidence is preclinical; human benefit is unestablishedDo MOTS-c and SS-31 improve energy or exercise performance in humans, and how are they different?
Mitochondrial signaling and membrane targeting are distinct approaches, with different human evidence.
MOTS-c performance findings are predominantly preclinical; SS-31 human trials have mixed, condition-specific resultsCan Cerebrolysin improve cognition in healthy people, or is its evidence limited to neurological conditions?
A small healthy-volunteer experiment exists, but it is far from proof of durable cognitive enhancement.
Healthy-volunteer evidence is small and short-term; disease trials do not establish routine enhancementHow does acetylcholine affect memory, and do supplements like Alpha-GPC or citicoline actually improve cognition?
Supplying a precursor is not the same as proving better memory or preventing dementia.
Some small trials show selected memory effects; broad enhancement and dementia prevention remain unprovenWhy are anticholinergic medications linked to dementia, and does occasional Benadryl use carry the same concern as long-term use?
Acute cognitive effects and an observational long-term association are different questions.
Higher cumulative exposure is associated with dementia in older adults; causation and occasional-use risk remain uncertainDo Alzheimer’s drugs like donepezil and memantine slow the disease itself, or mainly help with symptoms?
Supporting cognition and daily function is valuable, but differs from modifying the underlying pathology.
Randomized trials support symptomatic benefit; these drugs do not establish reversal of neurodegenerationDo newer Alzheimer’s treatments that remove amyloid actually preserve memory and independence, and what are their risks?
Modest average slowing of decline in selected early disease, balanced against monitoring and potentially serious adverse effects.
Phase 3 trials demonstrate slower cognitive and functional decline, not restored memory or a cureDoes clenbuterol actually build muscle in humans, or only burn fat?
Recent trials show anabolic effects alongside important tradeoffs.
Small randomized human trials show lean-mass effects; long-term safety is unresolvedWhat happens when you stop taking a peptide? Do the benefits reverse?
Ongoing drug effects, durable recovery, and what withdrawal studies actually show.
Weight regain after GLP-1 withdrawal is demonstrated; healing durability is uncertainCan Primobolan, Masteron, or Equipoise reliably replace an aromatase inhibitor?
Why a steroid ratio is not a validated estrogen-control formula.
Controlled human evidence for predictable estrogen control is lackingCan finasteride prevent hair loss from every anabolic steroid?
Blocking DHT production is different from blocking every androgen.
Evidence for male-pattern hair loss; no universal protection across AASIs low-dose trenbolone meaningfully safer, or just less likely to cause obvious side effects?
Less exposure does not establish a safe human threshold.
Robust controlled human safety data for bodybuilding use are absentAre oral steroids safer if used only before workouts, or injected instead?
Changing the route does not erase the molecule’s risks.
Liver risk depends on structure and exposure, not just swallowing versus injectingCan hard training raise AST and ALT, and how can you distinguish that from liver injury?
Muscle can release these enzymes too, but recent lifting does not automatically explain every elevation.
Controlled exercise research demonstrates prolonged enzyme elevations after weightliftingHow large does a calorie surplus need to be, and is rapid rebound weight mostly muscle?
Faster weight gain is not a direct measure of faster hypertrophy.
A small trained-lifter trial found clearer fat-gain effects than added muscle benefitsDo myostatin inhibitors actually build muscle in humans?
A real biological pathway does not validate every product sold under its name.
Some clinical agents change body composition; effects are product specificDoes tesamorelin specifically remove belly fat?
Visceral fat, pinchable fat, and general weight loss are different outcomes.
Randomized evidence concerns HIV-associated abdominal adiposityDoes taking T3 burn only fat, or can it cost muscle too?
Correcting hypothyroidism and creating thyroid excess are different situations.
Thyroid excess is not selective fat loss; the drug label warns against weight-loss useWhy aren’t peptides FDA-approved if they work so well?
Why promising biology and an approved treatment are different milestones.
Approval is specific to the drug product and indicationCan you build a tolerance to peptides, and does cycling prevent it?
Why fading nausea or a weight plateau does not prove a drug has stopped working.
Adaptation exists; preventive cycling is not establishedDo healing peptides like BPC-157 actually regrow tissue, or just reduce inflammation?
What repair experiments show, and why pain relief is not proof of regeneration.
Predominantly animal and laboratory evidence; limited human reportsDoes taking exogenous peptides shut down your body’s natural production?
Feedback, stimulation, and why the TRT analogy can mislead.
Hormonal feedback is real; permanent shutdown is not established for secretagoguesWhy do some people respond to peptides and others don’t?
True biological variation, different exposures, and misleading comparisons.
Response varies; anecdotes cannot identify the reasonAre there peptides that actually extend lifespan in humans, or is that speculative?
Mouse healthspan, human biomarkers, and demonstrated survival are different outcomes.
Human lifespan extension is not established for Epitalon, FOXO4-DRI, or MOTS-cWhat’s the difference between synthetic and bioidentical peptides?
How a molecule is made and whether it matches a human molecule are different questions.
Structure, exposure, and product quality matter more than marketing labelsWhy do some peptides have to be injected while others can be oral or intranasal?
Digestion, tissue barriers, and the formulation behind a usable dose.
Absorption must be demonstrated for each formulation and routeWhy do peptides need to be refrigerated, and what happens if they aren’t?
Temperature matters, but storage rules belong to the exact product.
Stability is formulation-specific; not every peptide requires refrigerationWhat’s the difference between subcutaneous and intramuscular injection for peptides?
The tissue and formulation influence absorption; faster does not automatically mean better.
Route comparisons are product-specific, not a rule for all peptidesExplore the research in more depth
What has been studied for preserving muscle during weight loss?
Separate weight loss, lean mass and muscle function.
4 selected reading notes · Human and preclinical evidence where availableWhat changes with testosterone treatment?
Muscle, hormone exposure, energy, sexual function and health tradeoffs.
7 selected reading notes · Human and preclinical evidence where availableDo mitochondrial mechanisms translate into better performance?
Follow the path from cell respiration to measurable human function.
3 selected reading notes · Human and preclinical evidence where availableDoes more lean mass mean more strength?
Examine the difference between a body-composition signal and functional improvement.
3 selected reading notes · Human and preclinical evidence where availableHow do GLPs compare beyond the weight-loss headline?
Compare matched trials, body composition and treatment experience.
6 selected reading notes · Human and preclinical evidence where availableWhat does tendon-repair research actually demonstrate?
Distinguish animal mechanics, combinations and human recovery.
2 selected reading notes · Human and preclinical evidence where available